18.05.2013 | Stephen Roper, Marina Zemskova, Benjamin A. Neely, Arch Martin, Peng Gao, E. Ellen Jones, Andrew S. Kraft, Richard R ..., PROTEOMICS, 2013

Purpose Effectively identifying the proteins present in this cellular secretome is complicated due to the presence of cellular protein leakage and serum protein supplements in culture media. A metabolic labeling and click chemistry capture method is described that facilitates the ...

mehr

17.05.2013 | Sylvia Christakos, Martin Hewison, David G. Gardner, Carol L. Wagner, Igor N. Sergeev, Erica Rutten, Anastassios G. ..., Annals of the New York Academy of Sciences, 2013

In recent years, vitamin D has been received increased attention due to the resurgence of vitamin D deficiency and rickets in developed countries and the identification of extraskeletal effects of vitamin D, suggesting unexpected benefits of vitamin D in health and disease, beyond bone ...

mehr

16.05.2013 | Christoph Burkart, Kei‐ichiro Arimoto, Tingdong Tang, Xiuli Cong, Nengming Xiao, Yun‐Cai Liu, Sergei V. Kotenko, Les ..., EMBO Molecular Medicine, 2013

Abstract The theory of cancer immunoediting refers to mechanisms by which the immune system can suppress or promote tumour progression. A major challenge for the development of novel cancer immunotherapies is to find ways to exploit the immune system's antitumour activity while ...

mehr

15.05.2013 | Elisa Oricchio, Hans‐Guido Wendel, Annals of the New York Academy of Sciences, 2013

Recent technological advances allow analysis of genomic changes in cancer in unprecedented detail. The next challenge is to prioritize the multitude of genetic aberrations found and identify therapeutic opportunities. We recently completed a study that illustrates the use of unbiased ...

mehr

15.05.2013 | Biswadip Banerji, Sumit Kumar Pramanik, Priyankar Sanphui, Sameer Nikhar, Subhas Chandra Biswas, Chemical Biology & Drug Design, 2013

Abstract Cancer continues to be one of the biggest threats to the human civilization since there is no cure of it. Small heterocyclic molecule with low molecular weight and novel structural feature is therapeutically highly demanding. These molecules have the capability to disrupt ...

mehr

14.05.2013 | Mohammed O. Abdelaziz, Celestino Bonura, Aurora Aleo, Teresa Fasciana, Cinzia Calà, Caterina Mammina, Microbiology and Immunology, 2013

ABSTRACT Cephalosporin‐resistant Escherichia coli has been increasingly reported worldwide. In this study, 32 cephalosporin resistant E. coli isolates identified from cancer patients in Cairo, Egypt in 2009–2010 were analyzed. Twenty‐three were of phylogenetic group D, seven A and one ...

mehr

13.05.2013 | Tuan Zea Tan, Qing Hao Miow, Ruby Yun‐Ju Huang, Meng Kang Wong, Jieru Ye, Jieying Amelia Lau, Meng Chu Wu, Luqman Ha ..., EMBO Molecular Medicine, 2013

Abstract Epithelial ovarian cancer (EOC) is hallmarked by a high degree of heterogeneity. To address this heterogeneity, a classification scheme was developed based on gene expression patterns of 1538 tumours. Five, biologically distinct subgroups — Epi‐A, Epi‐B, Mes, Stem‐A and Stem‐B — ...

mehr

11.05.2013 | Zhao‐Shi Bao, Chuan‐Bao Zhang, Hong‐Jun Wang, Wei Yan, Yan‐Wei Liu, Ming‐Yang Li, Wei Zhang, CNS Neuroscience & Therapeutics, 2013

Summary Background The Cancer Genome Atlas (TCGA) has divided patients with glioblastoma multiforme (GBM) into four subtypes based on mRNA expression microarray. The mesenchymal subtype, with a larger proportion, is considered a more lethal one. Clinical outcome prediction is required ...

mehr

10.05.2013 | Megan S. Kane, Mark E. Lindsay, Daniel P. Judge, Jemima Barrowman, Colette Ap Rhys, Lisa Simonson, Harry C. Dietz, S ..., American Journal of Medical Genetics Part A, 2013

Abstract Hutchinson–Gilford Progeria Syndrome (HGPS) is a premature aging disorder caused by mutations in LMNA, which encodes the nuclear scaffold proteins lamin A and C. In HGPS and related progerias, processing of prelamin A is blocked at a critical step mediated by the zinc ...

mehr

10.05.2013 | David Lebwohl, Özlem Anak, Tarek Sahmoud, Judith Klimovsky, Ingrid Elmroth, Tomas Haas, Joseph Posluszny, Stephen Sa ..., Annals of the New York Academy of Sciences, 2013

Everolimus is a potent, oral inhibitor of the mammalian target of rapamycin (mTOR) that has been investigated in multiple clinical development programs since 1996. A unique collaboration between academic and pharmaceutical experts fostered research that progressed rapidly, with simultaneous ...

mehr